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Objective: To compare the effects of continuous and intermittent celecoxib treatment in patients with knee or
hip osteoarthritis in flare.
Methods: In this 24-week, prospective, randomised, double-blind, placebo-controlled study, patients were
randomly assigned to receive continuous (n = 62) or intermittent (n = 61) treatment with celecoxib 200 mg
once daily. The primary efficacy end point was the area under the curve (AUC) of the change in the Western
Ontario and McMaster Universities Osteoarthritis Index (WOMAC) total scores between baseline and week
24 divided by the time interval. Secondary end points included the percentage of days with intake of the flare
drug, the AUC of the change in the WOMAC total scores, the mean change from baseline in the WOMAC
scores, and the patient’s and physician’s global assessment of osteoarthritis.
Results: There were no significant differences between patients randomised to continuous or intermittent
treatment in the primary end point or most of the secondary end points, although a consistent trend supporting
continuous treatment was observed. The percentage of days with intake of the flare drug was significantly
lower (p = 0.031) in the group receiving continuous versus intermittent celecoxib. Both treatment regimens
were well tolerated.
Conclusion: The results of this pilot study indicate a potential clinical difference between continuous and
intermittent treatment with celecoxib, and may be useful in designing future trials. A larger trial on both
efficacy and safety outcomes is required for conclusive evidence in favour of either continuous or intermittent
treatment.
E
vidence for structure-modifying pharmacological agents
that directly interfere with the progression of osteoarthritis
is currently insufficient.1–4 The goal of treatment in patients
with osteoarthritis is still primarily to reduce the signs and
symptoms of the disease while maintaining quality of life and
functional independence.
Prostaglandins most probably have an important role in the
pathophysiology of osteoarthritis. Stimulation of articular
chrondrocytes by proinflammatory cytokines increases prosta-
glandin E2 synthesis, which coincides with the up regulation in
expression of cyclo-oxygenase (COX)2 but not of COX1.5–8
Raised production of prostaglandin E2 and COX2 has been
implicated in cartilage matrix destruction.9 10 Therefore, COX2
may have a pivotal role in progression of osteoarthritis, and its
inhibition could potentially limit cartilage damage as well as
treat the signs and symptoms. However, the potential advan-
tages of using anti-inflammatory drugs in patients with
osteoarthritis need to be balanced against the risk of adverse
events, particularly cardiovascular thrombotic events.11–14
Numerous controlled clinical studies have proved the efficacy
and safety of treatment with the COX2-selective inhibitor,
celecoxib, in controlling the signs and symptoms of osteo-
arthritis.15–22 To date, no study has investigated the comparative
efficacy of every-day, fixed-dose COX2-selective inhibitor
therapy (continuous treatment) versus a strategy of taking
the same drug on demand (intermittent treatment) in patients
with osteoarthritis. Compared with intermittent treatment,
continuous treatment may, to some extent, control the disease
process better, potentially slowing disease progression.
Alternatively, intermittent treatment may effectively reduce
the signs and symptoms of osteoarthritis without causing the
adverse events that may be associated with continuous
treatment.
To investigate the feasibility of prospective clinical trials
evaluating intermittent and continuous use of anti-inflamma-
tory or analgesic drugs, we conducted a pilot, randomised study
to compare the effects of continuous and intermittent celecoxib
treatment over 6 months on the signs and symptoms of
osteoarthritis in patients with knee or hip osteoarthritis in flare.
METHODS
Patients
Patients were aged>40 years, with a diagnosis of osteoarthritis
of the knee or hip according to American College of
Rheumatology criteria,23 24 and needed frequent anti-inflam-
matory treatment for their condition (physician’s judgement
based on the patient’s clinical history). Patients were included
in the study if they had osteoarthritis in a flare state at the
baseline visit, a Functional Capacity Classification of I–III
according to Steinbrocker’s criteria25 at screening, and were
poor responders to paracetamol (acetaminophen; physician’s
judgement based on the patient’s clinical history).
Abbreviations: AUC, area under the curve; COX, cyclo-oxygenase;
NSAID, non-steroidal anti-inflammatory drug; VAS, visual analogue scale;




For patients receiving analgesic treatment for osteoarthritis
at screening, an osteoarthritis flare was recorded if the patient’s
and physician’s global assessment of osteoarthritis was fair,
poor or very poor at the baseline visit, and a comparison of the
screening and baseline assessments met at least three of the
following criteria: a baseline visual analogue scale (VAS) score
of at least 40 mm in the patient’s assessment of osteoarthritis
pain intensity, an increase of >2 points in the Osteoarthritis
Severity Index, or an increase of>1 grade in the patient’s or the
physician’s global assessment of arthritis. For patients who
were not receiving any treatment for their osteoarthritis and
whose osteoarthritis was not controlled at screening, an
osteoarthritis flare was recorded if they met at least three of
the following criteria during the baseline assessments: a
patient’s assessment of osteoarthritis pain intensity measure-
ment of at least 40 mm on the VAS, an Osteoarthritis Severity
Index of >7, or a patient’s or physician’s global assessment of
arthritis of poor or very poor.
Patients were excluded from the study if they had inflam-
matory arthritis, gout, acute joint trauma, an anticipated need
for any surgical or other invasive procedure during the course of
the study, an oesophageal or gastroduodenal ulcer within the
30 days before randomisation, active gastrointestinal disease,
severe renal or hepatic disease, a major bleeding disorder,
severe cardiac insufficiency, an anticipated need for
anti-inflammatory drugs other than the study drug, or known
hypersensitivity to COX2-selective inhibitors, salicylates, sul-
phonamides or non-selective non-steroidal anti-inflammatory
drugs (NSAIDs). Patients who were taking aspirin at doses
(325 mg/day for at least 30 days before the first dose of the
study drug continued their aspirin regimen.
The study was carried out according to the Declaration of
Helsinki and Good Clinical Practices guidelines. The study
protocol was approved by local institutional review boards/
independent ethics committees. All patients gave written
informed consent.
Study design
This was a 24-week, prospective, randomised, multicentre,
double-blind, placebo-controlled, parallel-group study to com-
pare the effects of continuous and intermittent treatment with
celecoxib on the signs and symptoms of knee or hip
osteoarthritis in flare. Figure 1A is a schematic representation
of the study design.
At screening, patients discontinued any analgesic they were
taking for osteoarthritis for 2–14 days, during which time
paracetamol at a maximum dose of 3 g/day was permitted. The
rescue drug was discontinued 8 h before baseline assessments.
The patients’ medical history was taken, and physical examina-
tion, clinical laboratory tests and osteoarthritis assessments
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Figure 1 (A) Schematic representation of trial design. (B) Patient disposition. ITT, intent-to-treat; NSAID, non-steroidal anti-inflammatory drug; OA,
osteoarthritis; QD, once daily.
100 Luyten, Geusens, Malaise, et al
www.annrheumdis.com
were performed at the screening, including the patient’s
assessment of pain intensity (VAS; 0 mm, no pain; 100 mm,
severe pain), the patient’s and physician’s global assessment of
osteoarthritis (5-point scale: 1, very good; 5, very poor) and the
Osteoarthritis Severity Index (sum of the scores (0–24) of
patient responses to seven inquiries related to osteoarthritis
pain, walking distance and activities of daily living; a lower
score indicates a better condition).26
At baseline, patients meeting the flare criteria underwent the
same tests performed at screening and were scored on the
Western Ontario and McMaster Universities Osteoarthritis
Index (WOMAC). Patients responded, by means of a VAS, to
24 component items (a lower WOMAC score indicated a better
condition).
Patients were randomised at baseline to either continuous or
intermittent celecoxib treatment using a computer-generated
randomisation schedule. All patients received celecoxib 200 mg
once daily for at least seven consecutive days at the start of the
study and discontinued it on resolution of osteoarthritis flare
symptoms or after a maximum of 21 days. Thereafter, in the
absence of flare, patients randomised to continuous treatment
took celecoxib 200 mg once daily for 24 weeks, whereas
patients randomised to intermittent treatment took matching
placebo. In the intermittent treatment arm, celecoxib use was
restricted to only periods of flare. This was achieved by clearly
labelling the study drug as ‘‘reserved for the treatment of an
osteoarthritis flare’’, or ‘‘medication to be taken outside of the
flare period’’. By contrast with the definition of flare at
baseline, which was a physician’s assessment based on well-
defined criteria, the definition of flare during the treatment
period was patients’ perception of their symptoms and signs, as
mentioned in the written consent.
All osteoarthritis assessments including the WOMAC Index
were performed at each study visit (weeks 2, 6, 12, 18 and 24
(¡3 days), or early termination). The patient’s global assess-
ment of osteoarthritis was always conducted before intake of
the flare drug. In both treatment arms, paracetamol could be
used as rescue drug during a flare at any time during the study,
except at least 8 h before osteoarthritis evaluations.
Study end points
The primary efficacy end point was the area under the curve
(AUC) of the change in the WOMAC total score between
baseline and week 24 (value at baseline minus the value at the
week 24 visit) divided by the time interval.
Secondary end points included the percentage of days with
intake of the flare drug, the AUC of the change in the WOMAC
total scores between baseline and weeks 2, 6, 12 and 18, and the
last assessment divided by the time interval (the last assess-
ment was defined as the last observation available for a
variable), the WOMAC total scores and subscores between
baseline and weeks 2, 6, 12, 18 and 24, and the last assessment,
the patient’s and physician’s global assessment of osteoarthritis
at weeks 2, 6, 12, 18 and 24, and the last assessment, the
number of paracetamol tablets (rescue drug) taken per day, and
the number and percentage of patients discontinuing the study
drug over time for treatment failure. The incidence of the
primary end point in the two treatment arms was further
assessed in retrospective analyses according to three stratified
groups: previous NSAID use, osteoarthritis of the knee or hip,
and the functional capacity class. The percentage of days with
intake of the flare drug was defined as the proportion of total
days in the treatment period that the patients judged
themselves to be in flare and hence took the flare drug
(celecoxib 200 mg once daily).
The investigators documented all adverse events (serious and
non-serious) directly observed or reported by the patient.
Statistical analyses
As this was a pilot study, and there have been no previous
investigations, a formal sample-size calculation was not per-
formed. On the basis of the recruitment capacity of participating
centres and a maximum recruitment period of 6 months, the total
number of patients to be included was fixed at 150. A total of 100
evaluable patients was aimed for (50 per treatment arm),
considering a drop-out rate of approximately 30%.
The homogeneity of the treatment groups at inclusion was
tested using a one-way analysis of variance for quantitative
parameters and a x2 test for qualitative parameters. All
Table 1 Patient demographics and baseline characteristics







Age in years, mean (SD) 64.6 (9.9) 64.9 (10.6) 0.849*
Weight in kg, mean (SD) 75.9 (11.9) 78.3 (15.7) 0.674
Sex, n (%) 1.000`
Male 12 (20) 12 (20)
Female 49 (80) 47 (80)
Functional Capacity Classification, n (%) 0.452
Class I 0 (0) 3 (5)
Class II 37 (61) 35 (59)
Class III 24 (39) 21 (36)
Pain, by VAS, 1–10 cm, mean (SD) 7.05 (1.65) 6.82 (1.60) 0.346
Osteoarthritis Severity Index Score, 0–24, mean (SD) 14.03 (2.84) 13.88 (2.94) 0.769
Index joint, n (%) 0.481`
Knee 48 (79) 50 (85)
Hip 13 (21) 9 (15)
Previous (within 30 days before inclusion) NSAID
use, n (%)
35 (57) 33 (56)
Previous (within 30 days before inclusion) paracetamol
use, n (%)
NSAID, non-steroidal anti-inflammatory drug; VAS, visual analogue scale.
*t test.
 Mann Whitney U test.
` Fisher’s test.
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statistical tests were performed two sided at the 5% level of
significance. The intent-to-treat population (all randomised
patients who took at least one dose of study drug) was
considered in the analyses.
The last-observation-carried-forward approach was used for
missing data or data obtained on days outside the observation
window. Mean changes in the WOMAC total scores over the
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Figure 2 (A) Mean area under the curve (AUC) between baseline and week 2, 6, 12, 18 and 24, and the last assessment of the change in the Western
Ontario and McMaster Universities Osteoarthritis Index (WOMAC) total scores, divided by the number of days between baseline and week 2, 6, 12, 18 and
24, and the last assessment, respectively. The primary efficacy end point was the mean AUC of the change in WOMAC total scores between baseline and
week 24, divided by the number of days between baseline and week 24. A positive AUC value corresponds to a decrease in the WOMAC total scores,
which indicates an improvement in condition. (B) AUC for the continuous treatment arm. (C) AUC for the intermittent treatment arm.
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analysis of covariance, with treatment and centre as the main
factors and baseline value as the covariate. The percentage of
days with intake of the flare drug was calculated on the basis of
the tablet count and was analysed using the Mann–Whitney U
test. The number of flare drug tablets taken in the two groups
was analysed by a two-group t test. In the retrospective
analyses, the comparison between the two arms for the primary
end point was performed using analysis of covariance, with
treatment as the main factor.
RESULTS
Patients
Patients (n = 131) were enrolled in 18 centres between June
2002 and April 2003. Of these, eight were not randomised as
they failed the screening requirements, and three were
randomised but there was no evidence that they used any
study drug. The remaining 120 patients constituted the intent-
to-treat population (fig 1B). Of these, 21 and 18 patients in the
continuous and intermittent treatment groups, respectively,
discontinued the study prematurely. The most common reasons
for discontinuation were adverse events (n = 15) and lack of
efficacy (n = 14; fig 1B). The mean age of patients across
treatment groups was 65 years and most patients were women.
We found no significant differences in the baseline character-
istics or medical history between the treatment groups (table 1).
Primary end point
The mean (standard deviation (SD)) change in the WOMAC
total score between baseline and week 24 as measured by the
AUC was 37.7 (40.00) in the continuous and 25.10 (32.01) in
the intermittent treatment group (fig 2A–C). We found a
numerical, but not significant, difference between the two
treatment groups (95% confidence interval (CI) for the
continuous treatment group 24.76 to 50.70, and that for the
intermittent treatment group 14.86 to 35.34).
Secondary end points
The mean (SD) percentage of days with intake of the flare drug
was significantly lower (p = 0.031) in the continuous than in
the intermittent treatment group (47.85 (20.70) and 52.79
(14.33), respectively).
The mean change in the WOMAC total scores as measured by
AUC increased numerically, but not significantly, from week 2
to week 18 for both treatment groups (fig 2A–C). We found no
significant differences between continuous or intermittent
treatment groups in the total WOMAC scores or any of the
Figure 3 (A) Mean change from baseline in the total Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) scores. Mean change
from baseline in the subscore categories (B) ‘‘how much pain do you have’’, (C) ‘‘amount of joint stiffness’’ and (D) ‘‘ability to move and to look after
yourself’’. A greater change in the WOMAC scores indicates greater improvement in condition. Filled circles, continuous treatment group; filled triangles,
intermittent treatment group. VAS, visual analogue scale.
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subscores. However, there was a general trend towards greater
mean changes in the WOMAC total scores from baseline in the
continuous treatment group than in the intermittent treatment
group at all time points (fig 3A). Similar trends were observed
for all three subscores (fig 3B–D). The greatest mean changes
occurred in the category ‘‘ability to move around and to look
after yourself’’ (fig 3D).
A higher percentage of patients from the continuous
treatment group rated their osteoarthritis as very good or good
than those in the intermittent treatment group at all time
points (table 2). More doctors rated osteoarthritis as very good
at all time points for those patients receiving continuous
treatment compared with those receiving intermittent treat-
ment (table 2). However, these trends were not supported by a
significant difference between the treatment groups (p = 0).
Patients receiving intermittent treatment took more rescue
drug daily (mean number of tablets 0.68 (SD 0.56)) than those
receiving continuous treatment (mean 0.50 (SD 0.47)). Also,
more patients (15%) from the intermittent treatment group
discontinued the study drug early because of treatment failure
than patients from the continuous treatment group (8%).
Again, the differences between the two groups were not
statistically significant for either measure.
Retrospective analyses
We found a significant difference in the incidence of the
primary efficacy variable between the two treatment arms for
patients who had not used NSAIDs previously (p = 0.03), but
not in those who had a record of previous NSAID use (table 3).
We also found no significant difference between the two
treatment arms for the joint involved or the functional capacity
class.
Safety
Both treatment regimens were well tolerated, with similar rates
of withdrawal due to adverse events (additional data are
available online at http://ard.bmjjournals.com/supplemental).
Most adverse events were mild or moderate in severity. Cardiac
failure was reported in 1 (2%) patient from the continuous
treatment group, but the study drug was not considered to be
the cause. Hypertension was observed in two patients overall, 1
(2%) from each treatment group, and this was believed to be
related to the study treatment in both cases. Aggravated
hypertension was observed in 1 (2%) patient from the
intermittent treatment group and was not related to the study
treatment.
DISCUSSION
Our results support the findings from a recently published
randomised controlled trial that treatment with celecoxib is
effective in managing the signs and symptoms of osteoarthritis
(regardless of whether the dose is part of a continuous or
intermittent regimen).27 To our knowledge, this is the first
prospective study to directly compare the effects of continuous
versus intermittent treatment with a COX2-selective inhibitor
in patients with osteoarthritis.
Except for the percentage of days with intake of the flare
drug, we found no significant differences between the
Table 2 Patient’s and physician’s global assessment of osteoarthritis after treatment with celecoxib 200 mg once daily—‘‘very
good’’ and ‘‘good’’ ratings
Patient’s assessment* (%) Physician’s assessment* (%)
Continuous treatment Intermittent treatment Continuous treatment Intermittent treatment
Very good Good Very good Good Very good Good Very good Good
Baseline 0 0 0 0 0 0 0 0
Week 2 0 31 0 27 0 27 0 31
Week 6 4 40 0 33 2 47 0 35
Week 12 4 46 2 26 6 46 0 28
Week 18 9 36 5 30 9 36 3 43
Week 24 12 41 5 32 12 46 0 44
Last assessment 10 33 3 27 10 36 0 32
*p.0.05 between the two treatment groups at all time points.
Table 3 Retrospective analyses: incidence of the primary end point according to location of
osteoarthritis, Functional Capacity Class and previous use of non-steroidal anti-inflammatory
drugs, after treatment with celecoxib 200 mg once daily
AUC of the change in WOMAC total score
between baseline and week 24, divided by the
number of days between baseline and week 24
p ValueContinuous treatment* Intermittent treatment*
Previous NSAID use
No 47.85 (34.49; 16) 26.46 (27.42; 19) 0.030
Yes 30.69 (42.74; 23) 23.88 (36.31; 21) 0.560
Location of osteoarthritis
Knee 33.58 (41.21; 28) 25.86 (31.87; 33) 0.422
Hip 39.47 (28.01; 11) 35.21 (36.01; 7) 0.230
Functional capacity class
Class I/II 36.39 (47.89; 22) 17.63 (27.13; 23) 0.153
Class III 75.92 (11.90; 17) 75.92 (11.90; 17) 0.603
AUC, area under the curve; NSAID, non-steroidal anti-inflammatory drug; WOMAC, Western Ontario and McMaster
Universities Osteoarthritis Index.
*Values are mean (SD; n).
p value with treatment as factor.
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continuous and intermittent regimens. However, a consistent
trend supporting a beneficial effect of continuous treatment
was observed for most of the end points. Pain and function
were improved by similar levels, regardless of whether patients
received a continuous or intermittent treatment with celecoxib,
as reflected by the mean change in WOMAC total score
between baseline and week 24. There was also a consistent
tendency for more improvement in patients receiving contin-
uous treatment, as evidenced by greater changes in WOMAC
scores, a reduced requirement for the flare drug, and improve-
ments in patient’s and physician’s assessment of osteoarthritis.
This was a pilot study with a relatively small patient
population, which limited the capacity to detect clinically
relevant differences between treatment groups. On the basis of
these results, an example for power calculation would be that
406 patients would be required to detect a medically relevant
and achievable difference of 0.197 times the SD in the primary
end point (equivalent to a difference of three flares) between
both treatment arms. However, another way of reviewing the
results of this study could be to opt for future studies on patient
preference for either a continuous or an intermittent regimen. A
crossover design would be needed for this purpose.
Additionally, differences in patient characteristics may also
have contributed to the lack of statistically significant
differences in our study, some of which were investigated in
retrospective analyses. Surprisingly, our results show that
continuous treatment was more beneficial than intermittent
treatment in patients without a record of previous NSAID use,
but not in those who had used NSAIDs before. The relevance of
these results remains to be elucidated.
An advantage of continuous treatment over intermittent
treatment could be that continuous treatment provides better
drug coverage and may be more effective in slowing disease
progression. However, data available currently are insufficient
to support this statement. Structural data from large prospec-
tive trials such as the Glucosamine/Chondroitin Arthritis
Intervention Trial27 will further tackle this question.
Conversely, intermittent treatment may be associated with
fewer adverse events compared with continuous treatment,
although this was not observed in our study. Both treatment
regimens were well tolerated and there was no marked
difference in the number or severity of adverse events between
groups.
The cardiovascular safety of non-selective NSAIDs and
COX2-selective inhibitors has recently become a prominent
issue. As continuous treatment with a non-selective NSAID or
COX2-selective inhibitor could increase the risk for cardiovas-
cular events in the long term, the potential for harm must be
carefully weighed against the benefits. The incidence of
cardiovascular events was very low in both treatment groups
in our study (additional data available online at http://
ard.bmjjournals.com/supplemental). However, the treatment
period was short (6 months) compared with previous long-
term studies that reported cardiovascular adverse events, which
were also dose dependent.11 12
Given the small size of this study, it is difficult to draw
definitive conclusions about the relative benefits of continuous
or intermittent treatment with celecoxib. Current recommen-
dations from regulatory agencies are to treat patients with
arthritis using non-selective NSAIDs and COX2-selective
inhibitors at the lowest dose for the shortest possible duration.
Therefore, as data available are yet insufficient to support either
a continuous or an intermittent regimen, we believe that
intermittent treatment could be tried first, failing which,
continuous treatment could be initiated. For many patients,
intermittent treatment with rescue drug may be more feasible
than continuous treatment. Further investigations with respect
to patient preference and disease progression are required.
Importantly, this study provides useful information for the
design of future studies.
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